Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254

Abstract excerpt

In the absence of a suitable carbohydrate-based vaccine, outer membrane vesicle (OMV) vaccines have been used to disrupt outbreaks of serogroup B meningococcal disease for more than 20 years. Proteomic technology provides physical methods with the potential to assess the composition and consistency of these complex vaccines. 2-DE, combined with MS, were used to generate a proteome map of an OMV vaccine, developed...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Infections and Vaccines
• Share to Pneumonia and Respiratory Infections
• Share to Virology and Viral Diseases